Allergic Conjunctivitis Treatment Market News size Have High Growth But May Foresee Even Higher Value 2019 – 2027

Admin

5 years ago

Allergic Conjunctivitis Treatment Market: Introduction

Allergic conjunctivitis is a type of eye inflammation which is a result of an allergic reaction caused by allergens such as pollen or mold spores, dust mites, and animal fur
The eyeball has a membrane known as conjunctiva which is vulnerable to irritation from allergens
Allergic conjunctivitis can be treated with the help of oral medications, eye drops, or immunotherapy

Some of the symptoms of allergic conjunctivitis are red or pink eyes, eye pain, swollen eyelids, and soreness
Drug treatments for allergic conjunctivitis include corticosteroids, olopatadine, emedastine, mast cell stabilizer, and medications for histamine control
Avoidance of allergens, artificial tear drops, and appropriate use of contact lenses are some of the practices employed to prevent allergic conjunctivitis
Allergic conjunctivitis is labeled by the International Ocular Inflammation Society (IOIS) as a type of ocular allergy that is categorized into two major types: seasonal allergic conjunctivitis and perennial allergic conjunctivitis
According to research published by the National Center for Biotechnology Information (NCBI), allergic conjunctivitis affects around 10% to 30% of the population globally

Key Drivers of Global Allergic Conjunctivitis Treatment Market

Increase in incidence and prevalence of allergic conjunctivitis

The global allergic conjunctivitis treatment market is driven by increase in incidence of allergic conjunctivitis. A research study published in 2017 by the National Institutes of Health (NIH) indicated that the number of patients being diagnosed with allergic conjunctivitis is increasing globally. This increase in incidence rate propels the global allergic conjunctivitis treatment market.

Get PDF Sample Copy of Report: (Including TOC, List of Tables & Figures, Chart) : https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=74664

Development of new treatment options

Pharmaceutical companies are developing new treatment options for allergic conjunctivitis such as Zerviate, EM-100, ADX-102, PRT-2761, and OTX-DP. For instance, EyeMax LLC’s EM-100 is currently in phase 3 of clinical trial, where its effectiveness is being checked in the treatment of ocular itching. Presently, around two third of new treatment options are in phase 2 or 3 of clinical trials. All these studies are being sponsored by major pharmaceutical companies. These factors fuel the growth of the global allergic conjunctivitis treatment market.

Rise in air pollution

The global allergic conjunctivitis treatment market is also driven by rise in air pollution in major cities across the globe. A research study published in 2016 by the National Center for Biotechnology Information (NCBI) revealed that ambient air pollution and weather changes are responsible for the occurrence as well as worsening of allergic conjunctivitis. This is attributed to the conjunctiva being sensitive to environmental particles along with direct contact of conjunctiva with the outside environment. Hence, rise in air pollution propels the global allergic conjunctivitis treatment market.

North America dominates Global Allergic Conjunctivitis Treatment Market

North America is the largest market for allergic conjunctivitis treatments due to high prevalence of allergic conjunctivitis. According to the American Society of Cataract and Refractive Surgery (ASCRS), around 50 million to 60 million people in the U.S. had allergic conjunctivitis in 2015.
The allergic conjunctivitis treatment market in Asia Pacific is expected to grow at a rapid pace due to large population base leading to increase in demand for improved health care facilities
Rapid urbanization along with increased particulate pollution has augmented the incidence of allergic conjunctivitis in several countries in Asia such as India. However, a few factors such as lack of awareness among the general public regarding eye disorders and lack of health insurance restrain the market in the region.

Key Players operating in the Global Allergic Conjunctivitis Treatment Market

The global allergic conjunctivitis treatment market is consolidated due to presence of small number of major players
Demand for allergic conjunctivitis treatment has increased in both emerging and developed markets. This has resulted in a surge in the number of distributors and suppliers in emerging markets. Key players operating in the global allergic conjunctivitis treatment market are:
Akorn Incorporated
Allergan
Bausch Health Companies, Inc.
Novartis AG
Santen Pharmaceutical Co. Ltd.
Sun Pharma Advanced Research Company Ltd.
Ocular Therapeutix, Inc.
Sirion Therapeutics, Inc.
Boehringer Ingelheim International GmbH
Atopix Therapeutics Ltd.
Auven Therapeutics
Others

Global Allergic Conjunctivitis Treatment Market: Research Scope

The global allergic conjunctivitis treatment market can be segmented based on type, treatment, end-user, and region

Global Allergic Conjunctivitis Treatment Market, by Type

Global Allergic Conjunctivitis Treatment Market, by Treatment

Global Allergic Conjunctivitis Treatment Market, by End-user

Global Allergic Conjunctivitis Treatment Market, by Region

North America
- U.S.
- Canada
Europe
- Germany
- France
- U.K.
- Italy
- Spain
Asia Pacific
- China
- Japan
- India
- Australia & New Zealand
- Rest of Asia Pacific
Latin America
- Brazil
- Mexico
- Rest of Latin America
Middle East & Africa
- GCC Countries
- South Africa
- Rest of Middle East & Africa